Global Personalized Medicine Market
Global Personalized Medicine Market

Personalized Medicine Comprehensive Study by Type (Diagnostic, Therapeutics, Medical Care, Nutrition, Wellness), Application (Hospitals, Molecular Diagnostic Laboratories and Testing Centers, Academic Institutes), Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, Dietary Care Centers, Others), End User (Patients and Consumers, Health Care Providers, Health Care Providers, Biopharmaceutical Companies, Others) Players and Region - Global Market Outlook to 2025

Personalized Medicine Market Segmented into XX Submarkets. | Forecast Years: 2020- 2025  

May 2020 Edition 247 Pages 200 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Personalized Medicine Market Definition
Personalized medicine diagnosing, monitoring, and giving the treatment to the individual according to the segmentation of disease risks and characteristics of each patient. This approach relies on the scientific research results and how the person's molecular nature along with genetic profile makes them susceptible to the particular disease. The research on personalized medicine id increasing the ability to predict the medical treatment which can be safe and effective to people and which can not.

The market study is broken down by Type (Diagnostic, Therapeutics, Medical Care, Nutrition and Wellness), by Application (Hospitals, Molecular Diagnostic Laboratories and Testing Centers and Academic Institutes) and major geographies with country level splits.

Quest Diagnostic (United States), Laboratory Corporation (United States), Becton, Dickinson, and Company (United States), Abbott Laboratories (United States), Pfizer Inc. (United States), Siemens Healthineers AG (Germany), CardioDx, Inc., (United States), Atrium Innovations Inc. (Canada), QIAGEN (Germany), Proteostasis Therapeutics, Inc. (United States), Asuragen (United States), Illumina, Inc. (United States) and Amgen Inc. (United States) are some of the key players that are part of study coverage.

Segmentation Overview
AdvanceMarketAnalytics has segmented the market of Global Personalized Medicine market by Type, Application and Region.

On the basis of geography, the market of Personalized Medicine has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Distribution Channel, the sub-segment i.e. Hospitals Pharmacies will boost the Personalized Medicine market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End User, the sub-segment i.e. Patients and Consumers will boost the Personalized Medicine market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Leaders and their expansionary development strategies
On 3rd January 2020, Atrium Innovations, a globally-recognized leader in the development, manufacturing, and commercialization of innovative, science-based nutritional health products, takes the next step in the company's mission to expand into personalized nutrition with the acquisition of San Francisco-based LivingMatrix. LivingMatrix, a technology-based, data, and algorithm-driven personalized functional medicine platform, was designed by clinicians to help practitioners effectively evaluate and engage patients, create personalized, actionable care plans, and track patient health outcomes.
On 11th December 2019, Proteostasis Therapeutics to Initiate First-Ever Personalized Medicine-Based Clinical Trial, CHOICES, in European CF Patients with Genotypes Ineligible for Approved CFTR Modulators. Proteostasis Therapeutics, Inc. a clinical-stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF), today announced positive, initial ex-vivo results of PTI's proprietary cystic fibrosis transmembrane conductance regulator (CFTR) modulators, PTI-801, PTI-808, and PTI-428, in individuals with CF who are ineligible for the current standard of care CFTR modulator therapies due to their genotype.


Market Trend
  • Rising Impact on Both Clinical Research and Patient Care and Improvement in Technologies Used for Personalized Medicine

Market Drivers
  • Prevalence of Many Complicated Diseases Around the Globe
  • Need for the Understanding and Monitoring the Diseases

Opportunities
  • Growing Academic Research on Personalized Medicine
  • Boosting the Adoption of Personalized Medicine

Restraints
  • Risks Associated with Personalized Medicine

Challenges
  • Low Degree of Programs About Drug Discovery in Developing Regions of the World


Key Target Audience
Personalized Medicine Manufacturers, Personalized Medicine International traders, Personalized Medicine Distributors and Suppliers, Research and Development Institutes, Potential Investors, Regulatory Bodies and Others

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Type
  • Diagnostic
  • Therapeutics
  • Medical Care
  • Nutrition
  • Wellness
By Application
  • Hospitals
  • Molecular Diagnostic Laboratories and Testing Centers
  • Academic Institutes
By Distribution Channel
  • Hospitals Pharmacies
  • Retail Pharmacies
  • Dietary Care Centers
  • Others

By End User
  • Patients and Consumers
  • Health Care Providers
  • Health Care Providers
  • Biopharmaceutical Companies
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Prevalence of Many Complicated Diseases Around the Globe
      • 3.2.2. Need for the Understanding and Monitoring the Diseases
    • 3.3. Market Challenges
      • 3.3.1. Low Degree of Programs About Drug Discovery in Developing Regions of the World
    • 3.4. Market Trends
      • 3.4.1. Rising Impact on Both Clinical Research and Patient Care and Improvement in Technologies Used for Personalized Medicine
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Personalized Medicine, by Type, Application, Distribution Channel, End User and Region (value) (2014-2019)
    • 5.1. Introduction
    • 5.2. Global Personalized Medicine (Value)
      • 5.2.1. Global Personalized Medicine by: Type (Value)
        • 5.2.1.1. Diagnostic
        • 5.2.1.2. Therapeutics
        • 5.2.1.3. Medical Care
        • 5.2.1.4. Nutrition
        • 5.2.1.5. Wellness
      • 5.2.2. Global Personalized Medicine by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Molecular Diagnostic Laboratories and Testing Centers
        • 5.2.2.3. Academic Institutes
      • 5.2.3. Global Personalized Medicine by: Distribution Channel (Value)
        • 5.2.3.1. Hospitals Pharmacies
        • 5.2.3.2. Retail Pharmacies
        • 5.2.3.3. Dietary Care Centers
        • 5.2.3.4. Others
      • 5.2.4. Global Personalized Medicine by: End User (Value)
        • 5.2.4.1. Patients and Consumers
        • 5.2.4.2. Health Care Providers
        • 5.2.4.3. Health Care Providers
        • 5.2.4.4. Biopharmaceutical Companies
        • 5.2.4.5. Others
      • 5.2.5. Global Personalized Medicine Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Personalized Medicine: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2019)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Quest Diagnostic (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Laboratory Corporation (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Becton, Dickinson, and Company (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Abbott Laboratories (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Pfizer Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Siemens Healthineers AG (Germany)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. CardioDx, Inc., (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Atrium Innovations Inc. (Canada)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. QIAGEN (Germany)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Proteostasis Therapeutics, Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Asuragen (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Illumina, Inc. (United States)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. Amgen Inc. (United States)
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
  • 7. Global Personalized Medicine Sale, by Type, Application, Distribution Channel, End User and Region (value) (2020-2025)
    • 7.1. Introduction
    • 7.2. Global Personalized Medicine (Value)
      • 7.2.1. Global Personalized Medicine by: Type (Value)
        • 7.2.1.1. Diagnostic
        • 7.2.1.2. Therapeutics
        • 7.2.1.3. Medical Care
        • 7.2.1.4. Nutrition
        • 7.2.1.5. Wellness
      • 7.2.2. Global Personalized Medicine by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Molecular Diagnostic Laboratories and Testing Centers
        • 7.2.2.3. Academic Institutes
      • 7.2.3. Global Personalized Medicine by: Distribution Channel (Value)
        • 7.2.3.1. Hospitals Pharmacies
        • 7.2.3.2. Retail Pharmacies
        • 7.2.3.3. Dietary Care Centers
        • 7.2.3.4. Others
      • 7.2.4. Global Personalized Medicine by: End User (Value)
        • 7.2.4.1. Patients and Consumers
        • 7.2.4.2. Health Care Providers
        • 7.2.4.3. Health Care Providers
        • 7.2.4.4. Biopharmaceutical Companies
        • 7.2.4.5. Others
      • 7.2.5. Global Personalized Medicine Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Personalized Medicine: by Type(USD Million)
  • Table 2. Personalized Medicine Diagnostic , by Region USD Million (2014-2019)
  • Table 3. Personalized Medicine Therapeutics , by Region USD Million (2014-2019)
  • Table 4. Personalized Medicine Medical Care , by Region USD Million (2014-2019)
  • Table 5. Personalized Medicine Nutrition , by Region USD Million (2014-2019)
  • Table 6. Personalized Medicine Wellness , by Region USD Million (2014-2019)
  • Table 7. Personalized Medicine: by Application(USD Million)
  • Table 8. Personalized Medicine Hospitals , by Region USD Million (2014-2019)
  • Table 9. Personalized Medicine Molecular Diagnostic Laboratories and Testing Centers , by Region USD Million (2014-2019)
  • Table 10. Personalized Medicine Academic Institutes , by Region USD Million (2014-2019)
  • Table 11. Personalized Medicine: by Distribution Channel(USD Million)
  • Table 12. Personalized Medicine Hospitals Pharmacies , by Region USD Million (2014-2019)
  • Table 13. Personalized Medicine Retail Pharmacies , by Region USD Million (2014-2019)
  • Table 14. Personalized Medicine Dietary Care Centers , by Region USD Million (2014-2019)
  • Table 15. Personalized Medicine Others , by Region USD Million (2014-2019)
  • Table 16. Personalized Medicine: by End User(USD Million)
  • Table 17. Personalized Medicine Patients and Consumers , by Region USD Million (2014-2019)
  • Table 18. Personalized Medicine Health Care Providers , by Region USD Million (2014-2019)
  • Table 19. Personalized Medicine Health Care Providers , by Region USD Million (2014-2019)
  • Table 20. Personalized Medicine Biopharmaceutical Companies , by Region USD Million (2014-2019)
  • Table 21. Personalized Medicine Others , by Region USD Million (2014-2019)
  • Table 22. South America Personalized Medicine, by Country USD Million (2014-2019)
  • Table 23. South America Personalized Medicine, by Type USD Million (2014-2019)
  • Table 24. South America Personalized Medicine, by Application USD Million (2014-2019)
  • Table 25. South America Personalized Medicine, by Distribution Channel USD Million (2014-2019)
  • Table 26. South America Personalized Medicine, by End User USD Million (2014-2019)
  • Table 27. Brazil Personalized Medicine, by Type USD Million (2014-2019)
  • Table 28. Brazil Personalized Medicine, by Application USD Million (2014-2019)
  • Table 29. Brazil Personalized Medicine, by Distribution Channel USD Million (2014-2019)
  • Table 30. Brazil Personalized Medicine, by End User USD Million (2014-2019)
  • Table 31. Argentina Personalized Medicine, by Type USD Million (2014-2019)
  • Table 32. Argentina Personalized Medicine, by Application USD Million (2014-2019)
  • Table 33. Argentina Personalized Medicine, by Distribution Channel USD Million (2014-2019)
  • Table 34. Argentina Personalized Medicine, by End User USD Million (2014-2019)
  • Table 35. Rest of South America Personalized Medicine, by Type USD Million (2014-2019)
  • Table 36. Rest of South America Personalized Medicine, by Application USD Million (2014-2019)
  • Table 37. Rest of South America Personalized Medicine, by Distribution Channel USD Million (2014-2019)
  • Table 38. Rest of South America Personalized Medicine, by End User USD Million (2014-2019)
  • Table 39. Asia Pacific Personalized Medicine, by Country USD Million (2014-2019)
  • Table 40. Asia Pacific Personalized Medicine, by Type USD Million (2014-2019)
  • Table 41. Asia Pacific Personalized Medicine, by Application USD Million (2014-2019)
  • Table 42. Asia Pacific Personalized Medicine, by Distribution Channel USD Million (2014-2019)
  • Table 43. Asia Pacific Personalized Medicine, by End User USD Million (2014-2019)
  • Table 44. China Personalized Medicine, by Type USD Million (2014-2019)
  • Table 45. China Personalized Medicine, by Application USD Million (2014-2019)
  • Table 46. China Personalized Medicine, by Distribution Channel USD Million (2014-2019)
  • Table 47. China Personalized Medicine, by End User USD Million (2014-2019)
  • Table 48. Japan Personalized Medicine, by Type USD Million (2014-2019)
  • Table 49. Japan Personalized Medicine, by Application USD Million (2014-2019)
  • Table 50. Japan Personalized Medicine, by Distribution Channel USD Million (2014-2019)
  • Table 51. Japan Personalized Medicine, by End User USD Million (2014-2019)
  • Table 52. India Personalized Medicine, by Type USD Million (2014-2019)
  • Table 53. India Personalized Medicine, by Application USD Million (2014-2019)
  • Table 54. India Personalized Medicine, by Distribution Channel USD Million (2014-2019)
  • Table 55. India Personalized Medicine, by End User USD Million (2014-2019)
  • Table 56. South Korea Personalized Medicine, by Type USD Million (2014-2019)
  • Table 57. South Korea Personalized Medicine, by Application USD Million (2014-2019)
  • Table 58. South Korea Personalized Medicine, by Distribution Channel USD Million (2014-2019)
  • Table 59. South Korea Personalized Medicine, by End User USD Million (2014-2019)
  • Table 60. Taiwan Personalized Medicine, by Type USD Million (2014-2019)
  • Table 61. Taiwan Personalized Medicine, by Application USD Million (2014-2019)
  • Table 62. Taiwan Personalized Medicine, by Distribution Channel USD Million (2014-2019)
  • Table 63. Taiwan Personalized Medicine, by End User USD Million (2014-2019)
  • Table 64. Australia Personalized Medicine, by Type USD Million (2014-2019)
  • Table 65. Australia Personalized Medicine, by Application USD Million (2014-2019)
  • Table 66. Australia Personalized Medicine, by Distribution Channel USD Million (2014-2019)
  • Table 67. Australia Personalized Medicine, by End User USD Million (2014-2019)
  • Table 68. Rest of Asia-Pacific Personalized Medicine, by Type USD Million (2014-2019)
  • Table 69. Rest of Asia-Pacific Personalized Medicine, by Application USD Million (2014-2019)
  • Table 70. Rest of Asia-Pacific Personalized Medicine, by Distribution Channel USD Million (2014-2019)
  • Table 71. Rest of Asia-Pacific Personalized Medicine, by End User USD Million (2014-2019)
  • Table 72. Europe Personalized Medicine, by Country USD Million (2014-2019)
  • Table 73. Europe Personalized Medicine, by Type USD Million (2014-2019)
  • Table 74. Europe Personalized Medicine, by Application USD Million (2014-2019)
  • Table 75. Europe Personalized Medicine, by Distribution Channel USD Million (2014-2019)
  • Table 76. Europe Personalized Medicine, by End User USD Million (2014-2019)
  • Table 77. Germany Personalized Medicine, by Type USD Million (2014-2019)
  • Table 78. Germany Personalized Medicine, by Application USD Million (2014-2019)
  • Table 79. Germany Personalized Medicine, by Distribution Channel USD Million (2014-2019)
  • Table 80. Germany Personalized Medicine, by End User USD Million (2014-2019)
  • Table 81. France Personalized Medicine, by Type USD Million (2014-2019)
  • Table 82. France Personalized Medicine, by Application USD Million (2014-2019)
  • Table 83. France Personalized Medicine, by Distribution Channel USD Million (2014-2019)
  • Table 84. France Personalized Medicine, by End User USD Million (2014-2019)
  • Table 85. Italy Personalized Medicine, by Type USD Million (2014-2019)
  • Table 86. Italy Personalized Medicine, by Application USD Million (2014-2019)
  • Table 87. Italy Personalized Medicine, by Distribution Channel USD Million (2014-2019)
  • Table 88. Italy Personalized Medicine, by End User USD Million (2014-2019)
  • Table 89. United Kingdom Personalized Medicine, by Type USD Million (2014-2019)
  • Table 90. United Kingdom Personalized Medicine, by Application USD Million (2014-2019)
  • Table 91. United Kingdom Personalized Medicine, by Distribution Channel USD Million (2014-2019)
  • Table 92. United Kingdom Personalized Medicine, by End User USD Million (2014-2019)
  • Table 93. Netherlands Personalized Medicine, by Type USD Million (2014-2019)
  • Table 94. Netherlands Personalized Medicine, by Application USD Million (2014-2019)
  • Table 95. Netherlands Personalized Medicine, by Distribution Channel USD Million (2014-2019)
  • Table 96. Netherlands Personalized Medicine, by End User USD Million (2014-2019)
  • Table 97. Rest of Europe Personalized Medicine, by Type USD Million (2014-2019)
  • Table 98. Rest of Europe Personalized Medicine, by Application USD Million (2014-2019)
  • Table 99. Rest of Europe Personalized Medicine, by Distribution Channel USD Million (2014-2019)
  • Table 100. Rest of Europe Personalized Medicine, by End User USD Million (2014-2019)
  • Table 101. MEA Personalized Medicine, by Country USD Million (2014-2019)
  • Table 102. MEA Personalized Medicine, by Type USD Million (2014-2019)
  • Table 103. MEA Personalized Medicine, by Application USD Million (2014-2019)
  • Table 104. MEA Personalized Medicine, by Distribution Channel USD Million (2014-2019)
  • Table 105. MEA Personalized Medicine, by End User USD Million (2014-2019)
  • Table 106. Middle East Personalized Medicine, by Type USD Million (2014-2019)
  • Table 107. Middle East Personalized Medicine, by Application USD Million (2014-2019)
  • Table 108. Middle East Personalized Medicine, by Distribution Channel USD Million (2014-2019)
  • Table 109. Middle East Personalized Medicine, by End User USD Million (2014-2019)
  • Table 110. Africa Personalized Medicine, by Type USD Million (2014-2019)
  • Table 111. Africa Personalized Medicine, by Application USD Million (2014-2019)
  • Table 112. Africa Personalized Medicine, by Distribution Channel USD Million (2014-2019)
  • Table 113. Africa Personalized Medicine, by End User USD Million (2014-2019)
  • Table 114. North America Personalized Medicine, by Country USD Million (2014-2019)
  • Table 115. North America Personalized Medicine, by Type USD Million (2014-2019)
  • Table 116. North America Personalized Medicine, by Application USD Million (2014-2019)
  • Table 117. North America Personalized Medicine, by Distribution Channel USD Million (2014-2019)
  • Table 118. North America Personalized Medicine, by End User USD Million (2014-2019)
  • Table 119. United States Personalized Medicine, by Type USD Million (2014-2019)
  • Table 120. United States Personalized Medicine, by Application USD Million (2014-2019)
  • Table 121. United States Personalized Medicine, by Distribution Channel USD Million (2014-2019)
  • Table 122. United States Personalized Medicine, by End User USD Million (2014-2019)
  • Table 123. Canada Personalized Medicine, by Type USD Million (2014-2019)
  • Table 124. Canada Personalized Medicine, by Application USD Million (2014-2019)
  • Table 125. Canada Personalized Medicine, by Distribution Channel USD Million (2014-2019)
  • Table 126. Canada Personalized Medicine, by End User USD Million (2014-2019)
  • Table 127. Mexico Personalized Medicine, by Type USD Million (2014-2019)
  • Table 128. Mexico Personalized Medicine, by Application USD Million (2014-2019)
  • Table 129. Mexico Personalized Medicine, by Distribution Channel USD Million (2014-2019)
  • Table 130. Mexico Personalized Medicine, by End User USD Million (2014-2019)
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Company Basic Information, Sales Area and Its Competitors
  • Table 142. Company Basic Information, Sales Area and Its Competitors
  • Table 143. Company Basic Information, Sales Area and Its Competitors
  • Table 144. Personalized Medicine: by Type(USD Million)
  • Table 145. Personalized Medicine Diagnostic , by Region USD Million (2020-2025)
  • Table 146. Personalized Medicine Therapeutics , by Region USD Million (2020-2025)
  • Table 147. Personalized Medicine Medical Care , by Region USD Million (2020-2025)
  • Table 148. Personalized Medicine Nutrition , by Region USD Million (2020-2025)
  • Table 149. Personalized Medicine Wellness , by Region USD Million (2020-2025)
  • Table 150. Personalized Medicine: by Application(USD Million)
  • Table 151. Personalized Medicine Hospitals , by Region USD Million (2020-2025)
  • Table 152. Personalized Medicine Molecular Diagnostic Laboratories and Testing Centers , by Region USD Million (2020-2025)
  • Table 153. Personalized Medicine Academic Institutes , by Region USD Million (2020-2025)
  • Table 154. Personalized Medicine: by Distribution Channel(USD Million)
  • Table 155. Personalized Medicine Hospitals Pharmacies , by Region USD Million (2020-2025)
  • Table 156. Personalized Medicine Retail Pharmacies , by Region USD Million (2020-2025)
  • Table 157. Personalized Medicine Dietary Care Centers , by Region USD Million (2020-2025)
  • Table 158. Personalized Medicine Others , by Region USD Million (2020-2025)
  • Table 159. Personalized Medicine: by End User(USD Million)
  • Table 160. Personalized Medicine Patients and Consumers , by Region USD Million (2020-2025)
  • Table 161. Personalized Medicine Health Care Providers , by Region USD Million (2020-2025)
  • Table 162. Personalized Medicine Health Care Providers , by Region USD Million (2020-2025)
  • Table 163. Personalized Medicine Biopharmaceutical Companies , by Region USD Million (2020-2025)
  • Table 164. Personalized Medicine Others , by Region USD Million (2020-2025)
  • Table 165. South America Personalized Medicine, by Country USD Million (2020-2025)
  • Table 166. South America Personalized Medicine, by Type USD Million (2020-2025)
  • Table 167. South America Personalized Medicine, by Application USD Million (2020-2025)
  • Table 168. South America Personalized Medicine, by Distribution Channel USD Million (2020-2025)
  • Table 169. South America Personalized Medicine, by End User USD Million (2020-2025)
  • Table 170. Brazil Personalized Medicine, by Type USD Million (2020-2025)
  • Table 171. Brazil Personalized Medicine, by Application USD Million (2020-2025)
  • Table 172. Brazil Personalized Medicine, by Distribution Channel USD Million (2020-2025)
  • Table 173. Brazil Personalized Medicine, by End User USD Million (2020-2025)
  • Table 174. Argentina Personalized Medicine, by Type USD Million (2020-2025)
  • Table 175. Argentina Personalized Medicine, by Application USD Million (2020-2025)
  • Table 176. Argentina Personalized Medicine, by Distribution Channel USD Million (2020-2025)
  • Table 177. Argentina Personalized Medicine, by End User USD Million (2020-2025)
  • Table 178. Rest of South America Personalized Medicine, by Type USD Million (2020-2025)
  • Table 179. Rest of South America Personalized Medicine, by Application USD Million (2020-2025)
  • Table 180. Rest of South America Personalized Medicine, by Distribution Channel USD Million (2020-2025)
  • Table 181. Rest of South America Personalized Medicine, by End User USD Million (2020-2025)
  • Table 182. Asia Pacific Personalized Medicine, by Country USD Million (2020-2025)
  • Table 183. Asia Pacific Personalized Medicine, by Type USD Million (2020-2025)
  • Table 184. Asia Pacific Personalized Medicine, by Application USD Million (2020-2025)
  • Table 185. Asia Pacific Personalized Medicine, by Distribution Channel USD Million (2020-2025)
  • Table 186. Asia Pacific Personalized Medicine, by End User USD Million (2020-2025)
  • Table 187. China Personalized Medicine, by Type USD Million (2020-2025)
  • Table 188. China Personalized Medicine, by Application USD Million (2020-2025)
  • Table 189. China Personalized Medicine, by Distribution Channel USD Million (2020-2025)
  • Table 190. China Personalized Medicine, by End User USD Million (2020-2025)
  • Table 191. Japan Personalized Medicine, by Type USD Million (2020-2025)
  • Table 192. Japan Personalized Medicine, by Application USD Million (2020-2025)
  • Table 193. Japan Personalized Medicine, by Distribution Channel USD Million (2020-2025)
  • Table 194. Japan Personalized Medicine, by End User USD Million (2020-2025)
  • Table 195. India Personalized Medicine, by Type USD Million (2020-2025)
  • Table 196. India Personalized Medicine, by Application USD Million (2020-2025)
  • Table 197. India Personalized Medicine, by Distribution Channel USD Million (2020-2025)
  • Table 198. India Personalized Medicine, by End User USD Million (2020-2025)
  • Table 199. South Korea Personalized Medicine, by Type USD Million (2020-2025)
  • Table 200. South Korea Personalized Medicine, by Application USD Million (2020-2025)
  • Table 201. South Korea Personalized Medicine, by Distribution Channel USD Million (2020-2025)
  • Table 202. South Korea Personalized Medicine, by End User USD Million (2020-2025)
  • Table 203. Taiwan Personalized Medicine, by Type USD Million (2020-2025)
  • Table 204. Taiwan Personalized Medicine, by Application USD Million (2020-2025)
  • Table 205. Taiwan Personalized Medicine, by Distribution Channel USD Million (2020-2025)
  • Table 206. Taiwan Personalized Medicine, by End User USD Million (2020-2025)
  • Table 207. Australia Personalized Medicine, by Type USD Million (2020-2025)
  • Table 208. Australia Personalized Medicine, by Application USD Million (2020-2025)
  • Table 209. Australia Personalized Medicine, by Distribution Channel USD Million (2020-2025)
  • Table 210. Australia Personalized Medicine, by End User USD Million (2020-2025)
  • Table 211. Rest of Asia-Pacific Personalized Medicine, by Type USD Million (2020-2025)
  • Table 212. Rest of Asia-Pacific Personalized Medicine, by Application USD Million (2020-2025)
  • Table 213. Rest of Asia-Pacific Personalized Medicine, by Distribution Channel USD Million (2020-2025)
  • Table 214. Rest of Asia-Pacific Personalized Medicine, by End User USD Million (2020-2025)
  • Table 215. Europe Personalized Medicine, by Country USD Million (2020-2025)
  • Table 216. Europe Personalized Medicine, by Type USD Million (2020-2025)
  • Table 217. Europe Personalized Medicine, by Application USD Million (2020-2025)
  • Table 218. Europe Personalized Medicine, by Distribution Channel USD Million (2020-2025)
  • Table 219. Europe Personalized Medicine, by End User USD Million (2020-2025)
  • Table 220. Germany Personalized Medicine, by Type USD Million (2020-2025)
  • Table 221. Germany Personalized Medicine, by Application USD Million (2020-2025)
  • Table 222. Germany Personalized Medicine, by Distribution Channel USD Million (2020-2025)
  • Table 223. Germany Personalized Medicine, by End User USD Million (2020-2025)
  • Table 224. France Personalized Medicine, by Type USD Million (2020-2025)
  • Table 225. France Personalized Medicine, by Application USD Million (2020-2025)
  • Table 226. France Personalized Medicine, by Distribution Channel USD Million (2020-2025)
  • Table 227. France Personalized Medicine, by End User USD Million (2020-2025)
  • Table 228. Italy Personalized Medicine, by Type USD Million (2020-2025)
  • Table 229. Italy Personalized Medicine, by Application USD Million (2020-2025)
  • Table 230. Italy Personalized Medicine, by Distribution Channel USD Million (2020-2025)
  • Table 231. Italy Personalized Medicine, by End User USD Million (2020-2025)
  • Table 232. United Kingdom Personalized Medicine, by Type USD Million (2020-2025)
  • Table 233. United Kingdom Personalized Medicine, by Application USD Million (2020-2025)
  • Table 234. United Kingdom Personalized Medicine, by Distribution Channel USD Million (2020-2025)
  • Table 235. United Kingdom Personalized Medicine, by End User USD Million (2020-2025)
  • Table 236. Netherlands Personalized Medicine, by Type USD Million (2020-2025)
  • Table 237. Netherlands Personalized Medicine, by Application USD Million (2020-2025)
  • Table 238. Netherlands Personalized Medicine, by Distribution Channel USD Million (2020-2025)
  • Table 239. Netherlands Personalized Medicine, by End User USD Million (2020-2025)
  • Table 240. Rest of Europe Personalized Medicine, by Type USD Million (2020-2025)
  • Table 241. Rest of Europe Personalized Medicine, by Application USD Million (2020-2025)
  • Table 242. Rest of Europe Personalized Medicine, by Distribution Channel USD Million (2020-2025)
  • Table 243. Rest of Europe Personalized Medicine, by End User USD Million (2020-2025)
  • Table 244. MEA Personalized Medicine, by Country USD Million (2020-2025)
  • Table 245. MEA Personalized Medicine, by Type USD Million (2020-2025)
  • Table 246. MEA Personalized Medicine, by Application USD Million (2020-2025)
  • Table 247. MEA Personalized Medicine, by Distribution Channel USD Million (2020-2025)
  • Table 248. MEA Personalized Medicine, by End User USD Million (2020-2025)
  • Table 249. Middle East Personalized Medicine, by Type USD Million (2020-2025)
  • Table 250. Middle East Personalized Medicine, by Application USD Million (2020-2025)
  • Table 251. Middle East Personalized Medicine, by Distribution Channel USD Million (2020-2025)
  • Table 252. Middle East Personalized Medicine, by End User USD Million (2020-2025)
  • Table 253. Africa Personalized Medicine, by Type USD Million (2020-2025)
  • Table 254. Africa Personalized Medicine, by Application USD Million (2020-2025)
  • Table 255. Africa Personalized Medicine, by Distribution Channel USD Million (2020-2025)
  • Table 256. Africa Personalized Medicine, by End User USD Million (2020-2025)
  • Table 257. North America Personalized Medicine, by Country USD Million (2020-2025)
  • Table 258. North America Personalized Medicine, by Type USD Million (2020-2025)
  • Table 259. North America Personalized Medicine, by Application USD Million (2020-2025)
  • Table 260. North America Personalized Medicine, by Distribution Channel USD Million (2020-2025)
  • Table 261. North America Personalized Medicine, by End User USD Million (2020-2025)
  • Table 262. United States Personalized Medicine, by Type USD Million (2020-2025)
  • Table 263. United States Personalized Medicine, by Application USD Million (2020-2025)
  • Table 264. United States Personalized Medicine, by Distribution Channel USD Million (2020-2025)
  • Table 265. United States Personalized Medicine, by End User USD Million (2020-2025)
  • Table 266. Canada Personalized Medicine, by Type USD Million (2020-2025)
  • Table 267. Canada Personalized Medicine, by Application USD Million (2020-2025)
  • Table 268. Canada Personalized Medicine, by Distribution Channel USD Million (2020-2025)
  • Table 269. Canada Personalized Medicine, by End User USD Million (2020-2025)
  • Table 270. Mexico Personalized Medicine, by Type USD Million (2020-2025)
  • Table 271. Mexico Personalized Medicine, by Application USD Million (2020-2025)
  • Table 272. Mexico Personalized Medicine, by Distribution Channel USD Million (2020-2025)
  • Table 273. Mexico Personalized Medicine, by End User USD Million (2020-2025)
  • Table 274. Research Programs/Design for This Report
  • Table 275. Key Data Information from Secondary Sources
  • Table 276. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Personalized Medicine: by Type USD Million (2014-2019)
  • Figure 5. Global Personalized Medicine: by Application USD Million (2014-2019)
  • Figure 6. Global Personalized Medicine: by Distribution Channel USD Million (2014-2019)
  • Figure 7. Global Personalized Medicine: by End User USD Million (2014-2019)
  • Figure 8. South America Personalized Medicine Share (%), by Country
  • Figure 9. Asia Pacific Personalized Medicine Share (%), by Country
  • Figure 10. Europe Personalized Medicine Share (%), by Country
  • Figure 11. MEA Personalized Medicine Share (%), by Country
  • Figure 12. North America Personalized Medicine Share (%), by Country
  • Figure 13. Global Personalized Medicine share by Players 2019 (%)
  • Figure 14. Global Personalized Medicine share by Players (Top 3) 2019(%)
  • Figure 15. Global Personalized Medicine share by Players (Top 5) 2019(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Quest Diagnostic (United States) Revenue, Net Income and Gross profit
  • Figure 18. Quest Diagnostic (United States) Revenue: by Geography 2019
  • Figure 19. Laboratory Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 20. Laboratory Corporation (United States) Revenue: by Geography 2019
  • Figure 21. Becton, Dickinson, and Company (United States) Revenue, Net Income and Gross profit
  • Figure 22. Becton, Dickinson, and Company (United States) Revenue: by Geography 2019
  • Figure 23. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 24. Abbott Laboratories (United States) Revenue: by Geography 2019
  • Figure 25. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 26. Pfizer Inc. (United States) Revenue: by Geography 2019
  • Figure 27. Siemens Healthineers AG (Germany) Revenue, Net Income and Gross profit
  • Figure 28. Siemens Healthineers AG (Germany) Revenue: by Geography 2019
  • Figure 29. CardioDx, Inc., (United States) Revenue, Net Income and Gross profit
  • Figure 30. CardioDx, Inc., (United States) Revenue: by Geography 2019
  • Figure 31. Atrium Innovations Inc. (Canada) Revenue, Net Income and Gross profit
  • Figure 32. Atrium Innovations Inc. (Canada) Revenue: by Geography 2019
  • Figure 33. QIAGEN (Germany) Revenue, Net Income and Gross profit
  • Figure 34. QIAGEN (Germany) Revenue: by Geography 2019
  • Figure 35. Proteostasis Therapeutics, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 36. Proteostasis Therapeutics, Inc. (United States) Revenue: by Geography 2019
  • Figure 37. Asuragen (United States) Revenue, Net Income and Gross profit
  • Figure 38. Asuragen (United States) Revenue: by Geography 2019
  • Figure 39. Illumina, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 40. Illumina, Inc. (United States) Revenue: by Geography 2019
  • Figure 41. Amgen Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 42. Amgen Inc. (United States) Revenue: by Geography 2019
  • Figure 43. Global Personalized Medicine: by Type USD Million (2020-2025)
  • Figure 44. Global Personalized Medicine: by Application USD Million (2020-2025)
  • Figure 45. Global Personalized Medicine: by Distribution Channel USD Million (2020-2025)
  • Figure 46. Global Personalized Medicine: by End User USD Million (2020-2025)
  • Figure 47. South America Personalized Medicine Share (%), by Country
  • Figure 48. Asia Pacific Personalized Medicine Share (%), by Country
  • Figure 49. Europe Personalized Medicine Share (%), by Country
  • Figure 50. MEA Personalized Medicine Share (%), by Country
  • Figure 51. North America Personalized Medicine Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Quest Diagnostic (United States)
  • Laboratory Corporation (United States)
  • Becton, Dickinson, and Company (United States)
  • Abbott Laboratories (United States)
  • Pfizer Inc. (United States)
  • Siemens Healthineers AG (Germany)
  • CardioDx, Inc., (United States)
  • Atrium Innovations Inc. (Canada)
  • QIAGEN (Germany)
  • Proteostasis Therapeutics, Inc. (United States)
  • Asuragen (United States)
  • Illumina, Inc. (United States)
  • Amgen Inc. (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation